Electrospun Nanofiber Wound Dressing
topic
Electrospun wound dressings use biocompatible polymers (PCL at 10–15 wt% in DCM:DMF 3:1, PVA at 10 wt% in water, gelatin at 15 wt% in HFIP) deposited at 12–20 kV to produce 200–600 nm fiber mats at 20–50 g/m² basis weight. Porosity of 80–90% supports oxygen permeability (>2,000 g/m²/24h MVTR) and prevents bacterial ingress (pore diameter 0.5–2.0 µm). Drug-loaded nanofibers (tetracycline or silver sulfadiazine at 5–15 wt%) achieve sustained release over 7–14 days matching wound healing kinetics. Wound exudate absorption capacity of 5–15 g/g is comparable to commercial hydrocolloid dressings. In vivo wound closure 30–40% faster than gauze in diabetic wound models. ISO 10993-5 cytotoxicity testing confirms cellular biocompatibility at standard therapeutic loadings.
Role
Advanced wound care platform replicating extracellular matrix fiber architecture at nanoscale, providing simultaneous drug delivery, moisture balance, and bacterial barrier functions for chronic wound and surgical site infection management.